esophageal squamous cell carcinoma

Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard

A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatmen